Hairloss treatments like finasteride, dutasteride, minoxidil, and RU58841. Users discuss "DHT itch" at receding hairlines and suggest using dutasteride or ketoconazole shampoo for relief.
Hairloss treatments like Minoxidil, finasteride, and stem cell therapies exist, but a complete cure is hindered by genetic complexity and market dynamics. Cloning hair follicles is considered a potential solution, but it's currently not feasible.
PP405 is a new hairloss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.
Hairloss challenges and identity issues, with opinions on using finasteride, minoxidil, and hair transplants versus accepting baldness. Some find shaving more work, while others stress personal choice and self-perception.
Hairloss treatments include finasteride, minoxidil, microneedling, dutasteride, CB-03-01, RU-58841, and experimental options like KY-19382 and stem cell therapy. Some treatments are considered ineffective or risky, such as ketoconazole, PRP, and low-level laser therapy.
PP405 shows promise as a hairloss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.
Hairloss treatments like finasteride, minoxidil, and dutasteride are popular but often lead to side effects and mixed results. The discussion stresses consulting medical professionals and being wary of unproven treatments in the hairloss industry.
The conversation discusses various hairloss treatments, including Breezula, KX826, and PP405, with mixed opinions on their effectiveness compared to finasteride and minoxidil. Some users express skepticism about the new treatments, while others remain hopeful about future developments.
Veradermics' new hairloss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
New hairloss treatments like stem cells, hair cloning, and gt20029 are unlikely to be available in the next 5-10 years, with some trials possibly starting by 2026. Current treatments like Minoxidil and Finasteride have been used for decades, and new developments depend on funding and successful trials.
Hairloss progress pictures can be misleading due to differences in lighting, hair length, and wetness, making it hard to accurately assess changes. Treatments mentioned include minoxidil and finasteride, with some users expressing skepticism about their effectiveness.
Exploring hairloss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.
The conversation discusses the lack of updates on GT20029 for hairloss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
Hairloss can begin in early adolescence and cause mental anguish. Treatments mentioned include eating cruciferous vegetables, engaging in physical activity, and maintaining scalp hygiene.
Hairloss discussion involving finasteride's side effects and effectiveness. Users shared mixed experiences, with some reporting side effects and others seeing positive results.
The conversation is about hairloss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.
The conversation is about the anticipated release timeline for a hairloss treatment called GT20029. It may be available on the gray market in 1-2 years and officially in 3-4 years after completing clinical trials.
Hairloss treatments, with users discussing their experiences with both RU58841 and Pyrilutamide, noting that the latter has only recently become available but may yield better results in the long term.
The conversation discusses the safety and effectiveness of a hairloss drug, GT20029, and the possibility of infrequent application, with users hoping for once-daily use and speculating on the drug's duration of effect on the scalp. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
Hairloss treatments and the user's progress with taking finasteride and minoxidil orally, which has resulted in full recovery after 5 months. Users commented on this progress and discussed their own experiences or confusion about the treatments used.
Hairloss treatments, specifically the use of finasteride, microneedling and potentially oral minoxidil. People discussed their experiences with finasteride, its effects on sexual behaviors, as well as potential solutions such as tadalafil or using other growth factor signal peptides for hope in curing male pattern baldness.
Hairloss treatment with Fin/Min/Niz/Microneedling showed great results in 100 days. User suggests adding topical rosemary oil and oral castor oil for extra benefits.
Hairloss treatments still rely heavily on minoxidil, finasteride, and RU58841, with little innovation. Future treatments like stem cell therapy and RNA technology show promise but are not yet available.
Hairloss treatment using 1mg Fin daily and Nizoral shampoo twice a week for 10 months showed improvement after 6-10 months. No significant side effects experienced, except slightly watery semen.
Hairloss treatments, specifically, discussing the effectiveness and side effects of finasteride, minoxidil, and RU58841 in various microdoses. It also includes an updated graph which provides information on how different doses affect DHT levels, scalp skin and serum androgen levels, as well as hair count.
Hairloss treatments, specifically the use of Finasteride, Nizoral, and dermarolling; potential results from these treatments are discussed, along with potential side effects.
Hairloss theory suggests imbalance between Vitamin D Receptor (VDR) and Androgen Receptor (AR) activation. Proposed treatment includes upregulating VDR, downregulating AR, and improving mitochondrial health.
Hairloss treatments, such as Dutasteride, Minoxidil, and Finasteride. Advice is given to give the medications time to work and to consider a Hair Transplant in order to fill any gaps caused by continuing hairloss.
Clascoterone 5% topical solution shows promise for treating male-pattern hairloss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.